Relative Bioavailability and Food Effect of a Single Dose of Different Solid Formulations of BI 1358894 Compared to a Single Dose of the Reference Tablet Formulation of BI 1358894 Following Oral Administration Under Fed and Fasted Conditions in Healthy Male Subjects (an Open-label, Single-dose, Randomised, Incomplete Blocks Crossover Design Study)
Latest Information Update: 02 Mar 2025
At a glance
- Drugs BI 1358894 (Primary)
- Indications Major depressive disorder
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 09 Jul 2019 Status changed from active, no longer recruiting to completed.
- 15 May 2019 Status changed from recruiting to active, no longer recruiting.
- 09 Apr 2019 Status changed from not yet recruiting to recruiting.